🌟 Adakras 200 mg (Sotorasib) – Everest Pharma

Adakras 200 mg is a breakthrough oral targeted therapy containing Sotorasib, a first-in-class, highly selective KRAS G12C inhibitor. It represents a major advancement in the treatment of cancers driven by the KRAS G12C mutation — a mutation once considered “undruggable.”

💊 Composition

Each film-coated tablet contains:
👉 Sotorasib 200 mg

⚡ Indications

Adakras 200 mg is indicated for the treatment of:

• Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation, who have received at least one prior systemic therapy.

📌 Key Features

✅ First approved KRAS G12C inhibitor for targeted cancer therapy
✅ Specifically designed to inhibit KRAS G12C mutant proteins and block tumor growth
✅ Convenient once-daily oral dosing
✅ Manufactured by Everest Pharmaceuticals Ltd., ensuring high-quality, affordable oncology treatment options

📌 Category:

➡️ Oncology / Anti-cancer Medicine
➡️ Targeted Therapy / Precision Medicine
➡️ KRAS G12C Inhibitor (Small Molecule Inhibitor)

---

🧬 Therapeutic Class:

• Selective KRAS G12C inhibitor

• Protein kinase inhibitor

---

💡 Indication-specific Category:

• Non-small cell lung cancer (NSCLC) therapy

• Molecular targeted treatment for KRAS G12C mutation-positive cancers

🕒 Dosage & Administration

• Recommended dose: 960 mg (usually 4 x 200 mg tablets) taken orally once daily

• Should be taken at the same time each day

• Can be taken with or without food

Note: Dose adjustments may be necessary based on tolerability or adverse events.

🏭 Manufacturer

Everest Pharmaceuticals Ltd.
A trusted name in global oncology care, delivering innovative and cost-effective medicines to improve patient outcomes.

🚀 Why Choose Adakras?

Adakras 200 mg offers a targeted, personalized approach to lung cancer treatment for patients with KRAS G12C mutations — providing new hope in cases where traditional therapies may have failed.